CM-101, a CCL24 neutralizing antibody, has been recently studied in patients with non-alcoholic steatohepatitis in a phase IIa proof-of-concept study. We caught up with Prof Rifaat Safadi (The Liver Institute, Hadassah Medical Organization, Hadassah Hebrew University Medical Center, Jerusalem, Israel) to discuss the primary and secondary endpoints and how well they were achieved, and the next steps in the clinical development of CM-101.
The abstract entitled ‘Phase 2a study of CM-101, a CCL24 neutralizing antibody, in patients with nonalcoholic steatohepatitis: a proof-of-concept study‘ was presented at EASL 2023, 21–24 June 2023, Vienna, Austria.
Questions:
- What were the primary and secondary endpoints and how well were they achieved? (0:14)
- What will be the next steps in the clinical development of CM-101? (4:41)
Disclosures: Rifaat Safadi is a consultant for Chemomab.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Atiya Henry.
Filmed in coverage of EASL 2023
Access further content on liver disorders
